Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00559988 · ClinicalTrials.gov registry record · Phase 4
Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk
A Phase 4 study, sponsored by Biotronik.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2,718
- Enrollment target
NCT00559988 is a Phase 4 study that was terminated before completion, run by Biotronik. The registered enrollment target is 2,718 participants.
The verdict
NCT00559988, a Phase 4 study, was terminated before completion, sponsored by Biotronik.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2,718 participants
- Enrollment target
Study Summary
The IMPACT Study will investigate the potential clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) technology and a predefined anticoagulation plan compared to conventional device evaluation and physician-directed anticoagulation in patients with implanted dual-chamber defibrillators or cardiac resynchronization therapy devices.
Interventions
- DRUG Home Monitoring Guided OAC
- DRUG Physician-Directed OAC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,718 participants |
| Start Date | 2008-02 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00559988
The ClinicalTrials.gov registry entry for NCT00559988 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2,718 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotronik, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Home Monitoring Guided OAC is the first listed.
NCT00559988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00559988 about?
NCT00559988 is a clinical study titled "Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk". The IMPACT Study will investigate the potential clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) technology and a predefined anticoagulation plan compared to conventional device evaluation and physician-directed anticoagulation in patients with implanted dual-chamber defibrilla...
What is the current status of trial NCT00559988?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2,718 participants. The study started on 2008-02. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00559988?
The interventions under investigation include: Home Monitoring Guided OAC (DRUG), Physician-Directed OAC (DRUG).
Who is sponsoring clinical trial NCT00559988?
This trial is sponsored by Biotronik, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.